	Model-estimated annual rates (95% CI)			
	FF/UMEC/VI	UMEC/VI	Rate ratio (95% CI); p-value	Annual rate reduction, % (95% CI)
On-treatment moderate/severe exacerbation				
Overall (n=6214)	0.91 (0.87, 0.95)	1.21 (1.14, 1.29)	0.75 (0.70, 0.81); p<0.001	25 (19, 30)
ICS use at screening (n=4448)	0.98 (0.93, 1.03)	1.38 (1.29, 1.48)	0.71 (0.65, 0.77); p<0.001	29 (23, 35)
No ICS use at screening (n=1766)	0.73 (0.67, 0.80)	0.83 (0.73, 0.94)	0.88 (0.76, 1.03); p=0.115	12 (−3, 24)
On-treatment severe exacerbation				
Overall (n=6214)	0.13 (0.12, 0.14)	0.19 (0.17, 0.22)	0.66 (0.56, 0.78); p<0.001	34 (22, 44)
ICS use at screening (n=4448)	0.14 (0.13, 0.16)	0.22 (0.19, 0.26)	0.65 (0.54, 0.80); p<0.001	35 (20, 46)
No ICS use at screening (n=1766)	0.09 (0.07, 0.11)	0.14 (0.10, 0.19)	0.65 (0.45, 0.93); p=0.018	35 (7, 55)